Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer.

Authors

Siraje Mahmud, Lisa Dwyer Orr, Mika Cline, Ayda Mirsalehi, Monica Lisi, Laura Ensley, Lorraine Brisbin, R Steven Paulson

Published in

The oncologist. Jun 27, 2026. Epub Jun 27, 2026.

Abstract

National clinical guidelines recommend biomarker testing to identify actionable alterations across cancers, supporting personalized treatment.
This retrospective database study characterized biomarker testing patterns among adult patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC), prostate cancer, or bladder cancer (January 2018-December 2022), receiving care within a large regional community oncology network in the West South-Central United States.
Of 18 491 patients with NSCLC, 20 810 with prostate cancer, and 4120 with bladder cancer, 7383 (40%), 4985 (24%), and 888 (22%), respectively, had metastatic disease. For these metastatic subgroups, biomarker testing rates were 80% (NSCLC), 34% (prostate), and 42% (bladder). Median time from disease diagnosis to first test order was 10 days (NSCLC), 98 days (prostate), and 23 days (bladder), with differences observed across racial and ethnic groups. Among tested patients, actionable mutations were identified in 29% (NSCLC), 25% (prostate), and 14% (bladder) of patients, and targeted therapy was received by 54%, 15%, and 38% of these patients, respectively. Among patients who initiated treatment prior to receipt of test results, 72% (NSCLC), 12% (prostate), and 30% (bladder) subsequently switched to targeted therapy following a positive result. Testing rates increased between 2018 and 2022 for all cohorts; result turnaround times improved in prostate and bladder cancers.
Biomarker testing was highest in metastatic NSCLC and lower in prostate and bladder cancer in this community oncology setting. Despite improvements over time, gaps remain in timely testing and use of targeted therapies, highlighting opportunities to optimize precision oncology implementation.

PMID:
42366674
Bibliographic data and abstract were imported from PubMed on 29 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.